Hyaluronic acid new formulation: Experience in HIV-associated facial lipoatrophy

Dermatology

Volumn 217, Issue 3, 2008, Pages 244-249

  Bechara, Falk G ^a,b   Gambichler, Thilo ^a   Brockmeyer, Norbert H ^a   Sand, Michael ^a   Altmeyer, Peter ^a   Hoffmann, Klaus ^a  

^a RUHR UNIVERSITY BOCHUM   (Germany)

^b ST JOSEF HOSPITAL   (Germany)

Author keywords

Human immunodeficiency virus; Hyaluronic acid; Lipoatrophy; Soft tissue augmentation

Indexed keywords

HYALURONIC ACID; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CONTUSION; DRUG SAFETY; ECCHYMOSIS; EDEMA; ERYTHEMA; ESTHETICS; FACIAL LIPOATROPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LIPOATROPHY; MALE; MEDICAL DOCUMENTATION; PATIENT SATISFACTION; PRIORITY JOURNAL; QUALITY OF LIFE; RATING SCALE; SWELLING; TREATMENT OUTCOME;

ADULT; ESTHETICS; FACIAL DERMATOSES; HIV-ASSOCIATED LIPODYSTROPHY SYNDROME; HUMANS; HYALURONIC ACID; MALE; MIDDLE AGED; PATIENT SATISFACTION; PILOT PROJECTS; PROSPECTIVE STUDIES; PROSTHESES AND IMPLANTS; QUALITY OF LIFE;

EID: 47949106609     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000148252     Document Type: Article

References (28)

1. Carr A, Cooper DA: Adverse effects of antiretroviral therapy. Lancet 2000;356:1423-1430.
2. Collins E, Wagner C, Walmsley S: Psychosocial impact of the lipodystrophy syndrome in HIV infection. AIDS Read 2000;10:546-550.
3. James J, Carruthers A, Carruthers J: HIV-associated facial lipoatrophy. Dermatol Surg 2002;28:979-986.
4. Silvers S, Eviatar JA, Evachez MI, Pappas AL: Prospective, open-label, 18-month trial of calcium hydroxylapatite (Radiesse) for facial soft-tissue augmentation in patients with human immunodeficiency virus-associated lipoatrophy: one-year durability. Plast Reconstr Surg 2006;118(3 suppl):34S-45S.
5. Sunderkötter C, Weiss JM, Bextermöller R, Löffler H, Schneider D: Post-marketing surveillance on treatment of 5,665 patients with atopic dermatitis using the alcineurin inhibitor pimecrolimus: positive effects on major symptoms of atopic dermatitis and on quality of life. J Dtsch Dermatol Ges 2006;4:301-306.
6. Mayrshofer F, Hertl M, Sinkgraven R, Sticherling M, Pfeiffer C, Zillikens D, Messer G, Rzany B: Significant decrease in quality of life in patients with pemphigus vulgaris: results from the German Bullous Skin Disease (BSD) Study Group. J Dtsch Dermatol Ges 2005;3:431-435.
7. Finlay AY, Khan GK: Dermatology Life Quality Index (DLQI): a simple practical measure for routine clinical use. Clin Exp Dermatol 1994;19:210-216.
8. Wanke CA, Falutz JM, Shevitz A, Phair JP, Kotler DP: Clinical evaluation and management of metabolic and morphologic abnormalities associated with human immunodeficiency virus. Clin Infect Dis 2002;34:248-259.
9. McComsey G, Walker UA: Role of mitochondria in HIV lipoatrophy: insight into pathogenesis and potential therapies. Mitochondrion 2004;4:111-118.
10. Jan V, Cervera P, Maachi M, Baudrimont M, Kim M, Vidal H, Girard PM, Levan P, Rozenbaum W, Lombès A, Capeau J, Bastard JP: Altered fat differentiation and adipocytokine expression are inter-related and linked to morphological changes and insulin resistance in HIV-1-infected lipodystrophic patients. Antivir Ther 2004;9:555-564.
11. Martinez E, Garcia-Viejo MA, Blanch J, Gatell JM: Lipodystrophy syndrome in patients with HIV infection: quality of life issues. Drug Saf 2001;24:157-166.
12. Tien PC, Grunfeld C: What is HIV-associated lipodystrophy? Defining fat distribution changes in HIV infection. Curr Opin Infect Dis 2004;17:27-32.
13. Cheng JT, Perkins SW, Hamilton MM: Collagen and injectable fillers. Otolaryngol Clin North Am 2001;9:405-411.
14. Alster TS, West TB: Human-derived and new synthetic injectable materials for soft-tissue augmentation: current status and role in cosmetic surgery. Plast Reconstr Surg 2000;105:2515-2524.
15. Narins R, Brandt F, Leyden J, Lorenc ZP, Rubin M, Smith S: A randomized, double blind, multicenter comparison of the efficacy and tolerability of Restylane versus Zyplast for the corrections of nasolabial folds. Dermatol Surg 2003;29:588-595.
16. Comite SL, Liu JF, Balasubramanian S, Christian MA: Treatment of HIV associated facial lipoatrophy with Radiance FN (Radiesse). Dermatol Online J 2004;10:2.
17. Moyle GJ, Lysakova L, Brown S, Sibtain N, Healy J, Priest C, Mandalia S, Barton SE: A randomized open-label study of immediate versus delayed polylactic acid injections for the cosmetic management of facial lipoatrophy in persons with HIV infection. HIV Med 2004;5:82-87.
18. Humble G, Mest D: Soft tissue augmentation using Sculptra. Facial Plast Surg 2004;20:157-163.
19. Valantin MA, Aubron-Olivier C, Ghosn J, Laglenne E, Pauchard M, Schoen H: Polylactic acid implants (New Fill) to correct facial lipoatrophy in HIV-infected patients: results of the open-label study VEGA. AIDS 2003;17:2471-2477.
20. Mori A, Lo Russo G, Agostini T, Pattarino J, Vichi F, Dini M: Treatment of human immunodeficiency virus-associated facial lipoatrophy with lipofilling and submalar silicone implants. J Plast Reconstr Aesthet Surg 2006;59:1209-1216.
21. Funk E, Bressler FJ, Brissett AE: Contemporary surgical management of HIV-associated facial lipoatrophy. Otolaryngol Head Neck Surg 2006;134:1015-1022.
22. Gooderham M, Solish N: Use of hyaluronic acid for soft tissue augmentation of HIV-associated facial lipodystrophy. Dermatol Surg 2005;31:104-108.
23. Jones D: HIV facial lipoatrophy: causes and treatment options. Dermatol Surg 2005;31:1519-1529.
24. Christensen L: Normal and pathologic tissue reactions to soft tissue gel fillers. Dermatol Surg 2007;33(suppl 2):168-175.
25. Duffy DM: Complications of fillers: overview. Dermatol Surg 2005;31:1626-1633.
26. Salek S, Roberts A, Finlay AY: The practical reality of using a patient-reported outcome measure in a routine dermatology clinic. Dermatology 2007;215:315-319.
27. Le Cleach L, Chassany O, Levy A, Wolkenstein P, Chosidow O: Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008;216:46-55.
28. Blanch J, Rousaud A, Martinez E, De Lazzari E, Milinkovic A, Peri JM, Blanco JL, Jaen J, Navarro V, Massana G, Gatell JM: Factors associated with severe impact of lipodystrophy on the quality of life of patients infected with HIV-1. Clin Infect Dis 2004;38:1464-1470.